Methods and compositions for treating ocular disorders

• US 6,855,690 B2
• Filed: 11/14/2002
• Issued: 02/15/2005
• Est. Priority Date: 06/01/2000
• Status: Expired due to Term

• Current Assignee: Children's Medical Center Corporation
• Original Assignee: Children's Medical Center Corporation
• Inventors: Benowitz, Larry I.
• Primary Examiner(s): Kunz, Gary
• Assistant Examiner(s): Gucker, Stephen
• Application Number:
  US10/294,965
• Publication Number:
  US 20030153501A1
• Time in Patent Office: 824 Days
• Field of Search: 514/2, 514/12, 514/912, 514/913
• US Class Current: 514/20.8
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/352 condensed with carbocyclic rings, e.g. methantheline cannabinoids A61K31/658
• CPC Class Codes: A61K 38/1738 Calcium binding proteins, e.g. calmodulin
• CPC Class Codes: A61K 38/1841 Transforming growth factor [TGF]
• CPC Class Codes: A61K 38/2278 Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61K 47/44 Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin synthetic glycerides, e.g. medium-chain triglycerides, A61K47/14
• CPC Class Codes: A61K 9/0048 Eye, e.g. artificial tears
• CPC Class Codes: A61K 9/2009 Inorganic compounds
• CPC Class Codes: A61K 9/2059 Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
• CPC Class Codes: Y10S 435/975 Kit

Abstract

The present invention provides a method for treating and/or preventing damage to a retina or optic nerve in a subject comprising administering to the subject a therapeutically effective amount of oncomodulin. Preferably, the subject is a mammal, most preferably, a human. In preferred embodiments, the oncomodulin may be used in combination with mannose, a mannose derivative and/or inosine.

Claims

1. A method for treating damage to a retina or optic nerve in a subject in need of such treatment comprising administering to the subject a therapeutically effective amount of oncomodulin.

2. The method of claim 1, further comprising administering to said subject a cAMP modulator.

3. The method of claim 2, wherein said cAMP modulator is non-hydrolyzable cAMP analogues, forskolin, adenylate cyclase activators, macrophage-derived factors that stimulate cAMP, macrophage activators, calcium ionophores, membrane depolarization, phosphodiesterase inhibitors, specific phosphodiesterase IV inhibitors, beta2-adrenoreceptor inhibitors or vasoactive intestinal peptide.

4. The method of claim 1, further comprising administering mannose or a mannose derivative to said subject.

5. The method of claim 1, further comprising administering inosine to said subject.

6. The method of claim 3, wherein the cAMP modulator is forskolin.

7. The method of claim 1, wherein the damage to the optic nerve is the result of glaucoma.

8. The method of claim 1, wherein the damage to the retina is the result of macular degeneration.

9. The method of claim 1, wherein the oncomodulin is administered topically to the eye of the subject.

10. The method of claim 1, wherein the oncomodulin is administered by intraocular injection.

11. The method of claim 1, wherein the oncomodulin is administered to the subject in a pharmaceutically acceptable formulation.

12. The method of claim 1, wherein the subject is a mammal.

13. The method of claim 12, wherein the mammal is a human.